-

Deepcell Raises $73 Million Series B Round to Advance Its AI-Powered Single Cell Analysis Platform

New funding to accelerate the scaling of operations and market introduction of its revolutionary “morpholomics” platform.

MENLO PARK, Calif.--(BUSINESS WIRE)--Deepcell, a life science company pioneering AI-powered single cell classification and isolation for basic and translational research, today announced that it has closed its $73 million Series B round of financing. The new funding will allow Deepcell to continue product development and enable early commercial introduction of a new standard for obtaining biological insights from single cell analysis. Deepcell’s platform combines advances in AI, proprietary microfluidics, high resolution optics, and a growing cell atlas with over 1 billion images to analyze and sort cells based on visual features. This allows researchers to characterize and gain new insights from single cells at levels of resolution previously unseen with other “omics” based tools.

This round of funding was led by Koch Disruptive Technologies and joined by new investors including Bridger Healthcare, Horizons Ventures, Casdin Capital and lead investors from previous rounds, Andreessen Horowitz and Bow Capital as well as Jeff Dean, Head of Google Brain, and Matt Mcllwain, Managing Director at Madrona Venture Group. This Series B financing brings Deepcell’s overall funding to nearly $100 million since the company was founded in 2017.

“The new funding will help us to accelerate our growth, develop our platform, and take a major step toward full commercialization,” said Maddison Masaeli, CEO and Co-founder of Deepcell. “The support we are receiving highlights the potential of Deepcell’s AI-powered single cell morphology analysis, and enables us to expand the team, transition to late-stage development and accelerate towards introducing our platform to a present and growing list of potential customers.”

Unlike other cell analysis approaches, Deepcell’s technology was developed to isolate and collect label-free single cells based on morphology, keeping the cell intact, which is critical for downstream biological characterization. By analyzing whole, unperturbed single cell populations instead of molecular targets on or within cells, Deepcell’s technology gives researchers access to a brand new dimension in cell biology and the ability to understand cellular heterogeneity in rich detail.

“Deepcell is advancing the use of computational methods with our deep learning capabilities to help fulfill the promise of precision medicine,” said Mahyar Salek, President, CTO and Co-founder of Deepcell. “AI can learn to identify cells based on visual differences that are hardly accessible to the human eye and can continually improve, thanks to our capability to sort cells and thereby elicit ground truth at scale. With training on billions of cell images and sorting cells, our AI technology connects morphology to multiomics, delivering unprecedented access to the exciting world of biology.”

“We are thrilled to support Deepcell’s vision as the market leader in single cell morpholomics,” said David Mauney, Managing Director at KDT and new Board member at Deepcell. “The company has clearly demonstrated the ability to provide unique biological insights previously unattained by existing approaches. We look forward to working with the team to expand their product offering and prepare for full commercialization.”

In addition to David Mauney, Blake Goodner and Matt Posard will join Deepcell’s Board of Directors. Mr. Goodner is a founding member of Bridger Management and Advisory Board Member with The Duke-Margolis Center for Health Policy, and Mr. Posard is a 30-year life sciences industry veteran and former Senior Vice President of Emerging Markets at Illumina.

For more information about Deepcell, go to www.deepcell.com.

About Deepcell

Deepcell is helping to advance precision medicine by combining advances in AI, cell classification and capture, and single-cell analysis to deliver novel insights through an unprecedented view of cell biology. Spun out of Stanford University in 2017, the company has created unique, microfluidics-based technology that uses continuously learning AI to classify cells based on detailed visual features and sort them without inherent bias. The Deepcell platform maintains cell viability for downstream single-cell analysis and can be used to isolate virtually any type of cell, even those occurring at frequencies as low as one in a billion. The technology will initially be available as a service for use in translational research as well as diagnostics and therapeutic development. Deepcell is privately held and based in Menlo Park, CA. For more information, please visit deepcellbio.com.

Contacts

Anthony Petrucci
Bioscribe
anthony@bioscribe.com
512-581-5442

Deepcell


Release Summary
Deepcell Raises $73 Million Series B Round to Advance Its AI-Powered Single Cell Analysis Platform
Release Versions

Contacts

Anthony Petrucci
Bioscribe
anthony@bioscribe.com
512-581-5442

More News From Deepcell

Deepcell Releases First-of-Its-Kind Single Cell Morphology Data Sets

MENLO PARK, Calif.--(BUSINESS WIRE)--Deepcell, a pioneer in AI-powered single cell analysis to fuel deep biological discoveries, today announced that it has released three data sets to enable researchers to explore novel high-dimensional morphology data. The data sets were generated on Deepcell’s high-throughput platform, comprised of imaging and sorting instrumentation, AI models, and a software suite. Deepcell is making the new data sets available online and at the Advances in Genome Biology...

Deepcell Expands Adoption of AI-Powered Morphology Characterization for Biological Researchers, Announces UCSF and TGen as First Installations in Technology Access Program

MENLO PARK, Calif.--(BUSINESS WIRE)--Deepcell, a life science company pioneering AI-powered single-cell morphology characterization technology for biology and translational research, today announced the roll out of the next stage of its Technology Access Program (TAP), providing access to the novel capabilities of the Deepcell platform. The University of California, San Francisco (UCSF) and the Translational Genomics Research Institute (TGen), part of City of Hope, are the initial locations to...

Deepcell Names Human Resources Veteran Kady Cooper as Head of People to Support Rapid Growth

MENLO PARK, Calif.--(BUSINESS WIRE)--Deepcell, a life science company pioneering AI-powered cell characterization and isolation for cell biology and translational research, today announced the appointment of Kady Cooper as Head of People. Kady has over 20 years of Human Resources experience supporting fast-growing start-ups and Fortune 100 companies in the San Francisco Bay Area. She joins Deepcell to build a world-class human resources function that supports the company’s exponential growth, t...
Back to Newsroom